keyword
MENU ▼
Read by QxMD icon Read
search

non cirrhotic portal hypertension

keyword
https://www.readbyqxmd.com/read/30003386/%C3%AE-blockers-improve-presinusoidal-portal-hypertension
#1
Michael Sørensen, Lars P Larsen, Gerda E Villadsen, Niels K Aagaard, Henning Grønbæk, Susanne Keiding, Hendrik Vilstrup
BACKGROUND: Presinusoidal portal hypertension is a clinically important cause of gastric and gastroesophageal varices. Whereas β-blockers have an established prophylactic role against bleeding from esophageal and gastric varices in portal hypertension due to cirrhosis, the effect on presinusoidal portal hypertension is unknown. AIMS: To evaluate the hemodynamic effect of β-blockers in non-cirrhotic patients with presinusoidal portal hypertension. METHODS: We measured the blood pressure gradient from spleen pulp to free hepatic vein in 12 patients with presinusoidal portal hypertension by combined hepatic vein catheterization and spleen pulp puncture while on and off β-blocker treatment (random sequence)...
July 12, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29996345/-diagnostic-value-of-transient-elastography-for-diagnosis-of-idiopathic-non-cirrhotic-portal-hypertension
#2
C Y He, Y Lyu, H Chen, H B Liu, Q H Wang, J H Fan, B H Luo, T L Yu, X L Yuan, J Tie, J Niu, W G Guo, Z X Yin, G H Han
No abstract text is available yet for this article.
April 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29996331/-cirrhotic-portal-hypertension-in-the-non-invasive-era-what-we-grasp
#3
X L Qi
The non-invasive era of portal hypertension in cirrhosis is approaching. We should seize the opportunity: then do learn to follow the recommended international guidelines for emerging non-invasive technologies and systematically utilize case resources of our country's for clinical verification; Secondly, we should pay attention to the cross-theory innovation of the middle level discipline in the process of technology development, and standardize the design and clinical registration in accordance with international diagnostic testing standards; Finally, a non-invasive technique for the treatment of cirrhotic portal hypertension was developed with a developmental perspective, enabling the transition from disease diagnosis and risk stratification to efficacy monitoring and prognosis prediction...
April 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29947694/higher-values-in-liver-elastography-and-meld-score-are-mortality-predictors-on-liver-transplant-waiting-list
#4
Lucas Souto Nacif, Denise C Paranagua-Vezozzo, Alina Matsuda, Venancio Avancini Ferreira Alves, Flair J Carrilho, Alberto Queiroz Farias, Luiz Carneiro D'Albuquerque, Wellington Andraus
BACKGROUND: Liver elastography have been reported in hepatocellular carcinoma (HCC) with higher values; however, it is unclear to identify morbimortality risk on liver transplantation waiting list. AIM: To assess liver stiffness, ultrasound and clinical findings in cirrhotic patients with and without HCC on screening for liver transplant and compare the morbimortality risk with elastography and MELD score. METHOD: Patients with cirrhosis and HCC on screening for liver transplant were enrolled with clinical, radiological and laboratory assessments, and transient elastography...
June 21, 2018: Arquivos Brasileiros de Cirurgia Digestiva: ABCD, Brazilian Archives of Digestive Surgery
https://www.readbyqxmd.com/read/29935993/non-cirrhotic-portal-hypertension-a-possibly-benign-but-complicated-disease
#5
EDITORIAL
Jonel Trebicka
No abstract text is available yet for this article.
June 4, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29931819/circulating-levels-of-3-hydroxymyristate-a-direct-quantification-of-endotoxemia-in-non-infected-cirrhotic-patients
#6
Delphine Weil, Jean-Paul Pais de Barros, Guillaume Mourey, Caroline Laheurte, Benoit Cypriani, Nicolas Badet, Eric Delabrousse, Emilie Grandclément, Vincent Di Martino, Philippe Saas, Laurent Lagrost, Thierry Thévenot
BACKGROUND&AIMS: The quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3-hydroxymyristate (3-HM), a lipid component of LPS, and to evaluate correlations between 3-HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage. METHODS: Plasma from 90 non-infected cirrhotic patients (30 Child-Pugh [CP]-A, 30 CP-B, 30 CP-C) was prospectively collected...
June 22, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29921982/the-soluble-guanylate-cyclase-stimulator-riociguat-reduces-fibrogenesis-and-portal-pressure-in-cirrhotic-rats
#7
Philipp Schwabl, Ksenia Brusilovskaya, Paul Supper, David Bauer, Philipp Königshofer, Florian Riedl, Hubert Hayden, Claudia Daniela Fuchs, Judith Stift, Georg Oberhuber, Stefan Aschauer, Diana Bonderman, Thorsten Gnad, Alexander Pfeifer, Frank Erhard Uschner, Jonel Trebicka, Nataliya Rohr-Udilova, Bruno Karl Podesser, Markus Peck-Radosavljevic, Michael Trauner, Thomas Reiberger
In cirrhotic patients, portal hypertension (PHT) deteriorates survival, yet treatment options are limited. A major contributor to increased intrahepatic vasoconstriction in PHT is dysfunctional nitric-oxide signaling. Soluble guanylate cyclase (sGC) is the receptor of nitric-oxide and can be stimulated by riociguat. Riociguat is approved for pulmonary hypertension but has not been studied in liver cirrhosis. In this study we assessed the effects of riociguat on PHT and liver fibrosis in cholestatic (bile duct ligation, BDL) and toxic (carbon-tetrachloride, CCl4) rat models...
June 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29847179/epidemiological-demographic-and-clinical-data-on-chronic-viral-hepatitis-c-in-tuscany
#8
Cristina Stasi, Caterina Silvestri, Roberto Berni, Maurizia Rossana Brunetto, Anna Linda Zignego, Cristina Orsini, Stefano Milani, Liana Ricciardi, Andrea De Luca, Pierluigi Blanc, Cesira Nencioni, Donatella Aquilini, Alessandro Bartoloni, Giampaolo Bresci, Santino Marchi, Franco Filipponi, Piero Colombatto, Paolo Forte, Andrea Galli, Sauro Luchi, Silvia Chigiotti, Alessandro Nerli, Giampaolo Corti, Rodolfo Sacco, Paola Carrai, Angelo Ricchiuti, Massimo Giusti, Paolo Almi, Andrea Cozzi, Silvia Carloppi, Giacomo Laffi, Fabio Voller, Francesco Cipriani
BACKGROUND: Recent introduction of direct antiviral agents (DAAs) has completely changed the scenario regarding hepatitis C virus (HCV) treatment. Certain countries' economic health programs prioritize DAAs according to specific clinical features of HCV-infected patients. The aim of this study was to define epidemiological, demographic and clinical characteristics of HCV-infected patients in the Tuscany region of central Italy. METHODS: We enrolled HCV patients with chronic viral hepatitis who were referred to the outpatient services of 16 hospitals in Tuscany from 1 January 2015 to 31 December 2015...
June 26, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29761167/phenotypic-spectrum-and-diagnostic-pitfalls-of-abcb4-deficiency-depending-on-age-of-onset
#9
Stephanie Barbara Schatz, Christoph Jüngst, Verena Keitel-Anselmo, Ralf Kubitz, Christina Becker, Patrick Gerner, Eva-Doreen Pfister, Imeke Goldschmidt, Norman Junge, Daniel Wenning, Stephan Gehring, Stefan Arens, Dirk Bretschneider, Dirk Grothues, Guido Engelmann, Frank Lammert, Ulrich Baumann
Genetic variants in the adenosine triphosphate-binding cassette subfamily B member 4 ( ABCB4 ) gene, which encodes hepatocanalicular phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid-associated cholelithiasis, and intrahepatic cholestasis of pregnancy. The aim of this multicenter project was to collect information on onset and progression of this entity in different age groups and to assess the relevance of this disease for the differential diagnosis of chronic liver disease...
May 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29651703/spectrum-of-histopathological-changes-in-patients-with-non-cirrhotic-portal-fibrosis
#10
Abhijit Chougule, Archana Rastogi, Rakhi Maiwall, Chhagan Bihari, Vikrant Sood, Shiv Kumar Sarin
BACKGROUND AND AIMS: Non-cirrhotic portal fibrosis (NCPF) is a clinical disorder characterized by features of portal hypertension in the absence of significant fibrosis. It is one of the commonest causes of portal hypertension in India. This study aimed to analyze histomorphological spectrum of NCPF in detail. METHODS AND RESULTS: There were 67 specimens from 66 patients which included 43 (65.2%) male and 23 (34.8%) female patients with a mean age of 31 years (range: 7-61 years)...
March 2018: Hepatology International
https://www.readbyqxmd.com/read/29644531/splanchnic-vein-thrombosis-in-the-myeloproliferative-neoplasms
#11
REVIEW
Imo J Akpan, Brady Lee Stein
PURPOSE OF REVIEW: To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis. RECENT FINDINGS: The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women...
April 11, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29644430/pathology-of-idiopathic-non-cirrhotic-portal-hypertension
#12
REVIEW
Maria Guido, Samantha Sarcognato, Diana Sacchi, Guido Colloredo
Idiopathic non-cirrhotic portal hypertension is an under-recognized vascular liver disease of unknown etiology, characterized by clinical signs of portal hypertension in the absence of cirrhosis. By definition, any disorder known to cause portal hypertension in the absence of cirrhosis and any cause of chronic liver disease must be excluded to make a diagnosis of idiopathic non-cirrhotic portal hypertension. However, the diagnosis is often difficult because the disease resembles cirrhosis and there is no gold standard test...
July 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29609064/massive-epithelioid-hemangioendothelioma-causing-noncirrhotic-portal-hypertension
#13
Amir Taefi, Karen Matsukuma, Eric Chak
No abstract text is available yet for this article.
March 31, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29564495/non-cirrhotic-portal-hypertension-an-imaging-review
#14
S Rajesh, Amar Mukund, Binit Sureka, Kalpana Bansal, Maxime Ronot, Ankur Arora
Non-cirrhotic portal hypertension (NCPH) comprises a group of diseases that are characterized by increased portal pressure in the absence of cirrhosis of the liver. It may arise as a result of either primary hepatic disease or the effects of systemic disorders on liver. The natural course of NCPH is largely indolent and benign with an overall better outcome than cirrhosis, as long as the complications of portal hypertension are properly managed and regular surveillance is carried out. However, due to the numerous and variable etiological factors and lack of standardized diagnostic criteria, this entity is under-recognized clinically as well as pathologically and often gets mislabeled as cryptogenic cirrhosis...
March 21, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29516016/portal-cavernoma-mimicking-pancreatic-malignancy
#15
Vivian M Ussui, Lavinia Goldstein, Enrico Souto, Cynthia Levy
Portal cavernoma colangiopathy (PCC) is an uncommon cause of portal hypertension, and it is an important differential diagnosis of pancreatic malignancy given the expanded network of collateral vessels. On imaging studies, portal cavernoma can be seen as a hypoechoic mass, possibly associated with distal common bile duct obstruction. Most cases occur in non-cirrhotic patients. During the symptomatic phase, these patients carry a high-risk of complications related to sustained biliary obstruction. We report a unique patient with obstructive jaundice and a presumed pancreatic mass that proved to be a portal cavernoma complicated by PCC in the setting of nodular regenerative hyperplasia of the liver...
2018: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29507470/propranolol-reduces-systemic-oxidative-stress-and-endotoxemia-in-cirrhotic-patients-with-esophageal-varices
#16
Dimitra Taprantzi, Dimitrios Zisimopoulos, Konstantinos C Thomopoulos, Iris Spiliopoulou, Christos D Georgiou, Georgios Tsiaoussis, Christos Triantos, Charalambos A Gogos, Chrisoula Labropoulou-Karatza, Stelios F Assimakopoulos
Background: The aim of the study was to investigate the effect of propranolol on systemic oxidative stress and endotoxemia in patients with liver cirrhosis and clinically significant portal hypertension evidenced by the presence of esophageal varices. Methods: Fourteen patients with liver cirrhosis and esophageal varices, not previously been treated with non-selective beta-blockers (NSBB), were prospectively started on propranolol and followed up for three months...
March 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29464506/idiopathic-portal-hypertension-and-extrahepatic-portal-venous-obstruction
#17
REVIEW
Rajeev Khanna, Shiv Kumar Sarin
BACKGROUND: Idiopathic portal hypertension (IPH) and extrahepatic portal venous obstruction (EHPVO) are non-cirrhotic vascular causes of portal hypertension (PHT). Variceal bleed and splenomegaly are the commonest presentations. AIM: The present review is intended to provide the existing literature on etiopathogenesis, clinical profile, diagnosis, natural history and management of IPH and EHPVO. RESULTS: IPH and EHPVO are both characterized by normal hepatic venous pressure gradient, moderate to massive splenomegaly with preserved liver synthetic functions...
February 2018: Hepatology International
https://www.readbyqxmd.com/read/29456411/clinical-utility-of-hepatitis-b-surface-antigen-kinetics-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients-during-long-term-entecavir-therapy
#18
Tien-Ching Lin, Yen-Cheng Chiu, Hung-Chih Chiu, Wen-Chun Liu, Pin-Nan Cheng, Chiung-Yu Chen, Ting-Tsung Chang, I-Chin Wu
AIM: To investigate the utility of hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B patients during long-term entecavir treatment. METHODS: This retrospective study included treatment-naïve chronic hepatitis B patients who received at least 2 years of consecutive entecavir treatment. Patients were followed up at three to six month intervals with liver biochemistry, hepatitis B virus DNA, and abdominal sonography. In hepatitis B e antigen (HBeAg)-positive patients, HBeAg levels were assessed every three to six month until results became negative...
February 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29429910/natural-history-of-patients-with-non-cirrhotic-portal-hypertension-comparison-with-patients-with-compensated-cirrhosis
#19
Stefania Gioia, Silvia Nardelli, Chiara Pasquale, Ilaria Pentassuglio, Valeria Nicoletti, Francesca Aprile, Manuela Merli, Oliviero Riggio
BACKGROUND: The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. AIM: To describe the clinical presentation and the outcomes of 89 patients with non-cirrhotic PH (25 with non-cirrhotic portal hypertension, INCPH, and 64 with chronic portal vein thrombosis, PVT) in comparison with 77 patients with Child A cirrhosis. METHODS: The patients were submitted to a standardized clinical, laboratory, ultrasonographic and endoscopic follow-up...
January 31, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29399280/collagen-proportionate-area-correlates-to-hepatic-venous-pressure-gradient-in-non-abstinent-cirrhotic-patients-with-alcoholic-liver-disease
#20
Sophie Restellini, Nicolas Goossens, Sophie Clément, Nicolas Lanthier, Francesco Negro, Laura Rubbia-Brandt, Laurent Spahr
AIM: To explore the relationship between collagen proportionate area (CPA) and portal hypertension-related clinical manifestations in alcoholic liver disease (ALD). METHODS: Retrospective study with chart review of patients with ALD adressed to our center between January 2012 and December 2013 for a transjugular liver biopsy (TJLB) and hepatic hemodynamic study. Patients were included if they met the following criteria: (1) Medical indication for a liver biopsy in the setting of ALD; (2) recent (< 15 d) clinical, radiological, endoscopic and biological data available; and (3) estimated follow-up of at least 6 mo...
January 27, 2018: World Journal of Hepatology
keyword
keyword
110495
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"